Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology therapies for the treatment of cancers with critical unmet medical need. Co.'s clinical pipeline consists of its main program, cirmtuzumab, a humanized monoclonal antibody that binds to Receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1), and TK216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. Co. is also developing a chimeric antigen receptor T-cells product candidate that targets ROR1. The ONCT stock yearly return is shown above.
The yearly return on the ONCT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ONCT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|